腹腔内灌注重组人p53腺病毒注射液及顺铂结合局部亚高温热疗治疗恶性腹水观察  被引量:5

Early efficacy study of intraperitoneal Ad-p53 and cisplatin in combination with regional thermotherapy in malignant ascites

在线阅读下载全文

作  者:秦苑[1] 任东 范宇飞 刘晓林 李定纲[1] 

机构地区:[1]北京市海淀医院肿瘤血液科,北京100080 [2]北京燕化医院肿瘤科,北京102500

出  处:《实用临床医药杂志》2011年第13期15-17,共3页Journal of Clinical Medicine in Practice

摘  要:目的探讨腹腔内灌注重组人p53腺病毒注射液(rAd-p53)及化疗联合区域热疗治疗恶性腹腔积液的临床疗效及毒副作用。方法 50例恶性腹水患者分为2组,观察组25例尽量引流后腔内注射rAd-p53 1×1012VP,48~72 h后腹腔内再注入顺铂40 mg/m2,帮助患者变换体位,当日行腹部亚高温射频透热热疗1 h,热疗2次/周,疗程共4周。对照组除不给予rAd-p53外,腔内化疗、热疗与观察组相同。结果观察组有效率(CR+PR+SD)为88.0%,对照组为64.0%(P〈0.05)。2组均偶有恶心、呕吐、皮下脂肪硬结等Ⅰ~Ⅱ度不良反应,观察组特有的不良反应主要为自限性发热。结论腔内rAd-p53联合化疗及局部热疗控制恶性腹腔积液疗效好、安全。Objective To evaluate the effects of intraperitoneal recombinant adenovirus p53 injection(rAd-p53) and cisplatin combined with regional thermotherapy on malignant peritoneal effusion.Methods Fifty patients with malignant ascites were treated in different groups as below: 25 patients were given intracavitary administration of rAd-p53 1×1012 VP after ascites drainage,48~72 h later cisplatin 40 mg/m2 was given by intraperitoneal injection weekly.Then 1 h of radio frequency thermotherapy(RFT) on abdomen followed,and RFT was operated twice a week.The treatment was repeated for 4 weeks.The other 25 patients just got cisplatin 40 mg/m2 intraperitoneal infusion after ascites drainage weekly and 1 h of abdominal regional RFT twice a week for 4 weeks.Results The overall response rate(CR+PR+SD) of 2 groups were 88.0% and 64.0%(P0.05).The toxicity of rAd-p53 was transient fever,and the adverse reaction of RFT was transient subcutaneous scleroma.No grade Ⅲ or grade Ⅳ toxic reactions were found.Conclusion It is safe and effective to treat malignant ascites with intraperitoneal Ad-p53 and cisplatin in combination with abdominal regional RFT.

关 键 词:重组人P53腺病毒注射液 恶性体腔积液 基因治疗 局部射频热疗 

分 类 号:R730.6[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象